[1] Braunwald E. The war against heart failure:the Lancet lec-ture[J]. Lancet, 2015, 385(9970):812-824. [2] Burchfield JS, Xie M, Hill JA. Pathological ventricular re-modeling:mechanisms:part 1of 2[J]. Circulation, 2013, 128(4):388-400. [3] 白晓洁, 郝峻涛, 封启龙. E4031对慢性心衰大鼠离体心脏功能和心肌细胞内静息Ca2+水平的影响[J]. 中国应用生理学杂志, 2014, 30(4):364-367. [4] Kho C, Lee A, Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling-targets for heartfailure therapy[J]. Nat Rev Cardiol, 2012, 9(12):717-733. [5] Wahlquist C, Jeong D, Rojas-Munoz A, et al. Inhibition ofmiR-25improves cardiac contractility in the failing heart[J]. Nature, 2014, 508(7497):531-535. [6] 苏志远, 叶小汉, 吴锦波. 心康方治疗慢性心力衰竭临床观察[J]. 新中医, 2016, 48(3):12-14. [7] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):98-122. [8] 白剑, 顾蓉, 王丙剑, 等. 过表达整合素连接激酶可改善慢性心力衰竭大鼠心功能[J]. 中华心血管病杂志, 2014, 42(3):225-229. [9] Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart fa ilure:analysis of recurrent cardiovascular events and mor-tality[J]. Circ Res, 2014, 114(1):101-108. [10] Greenberg B, Butler J, Felker GM, et al. Calcium upregu-lation by percutaneous administration of gene therapy in pa-tients with cardiac disease (CUPID 2):a randomised, multi-national, double-blind, placebo-controlled, phase 2b trial[J]. Lancet, 2016, 387(10024):1178-1186. [11] Alsaleh G, Gottenberg JE. Characterization of microRNAs and their targets[J]. Methods Mol Biol, 2014, 1142:55-63. [12] 吴锦波, 叶小汉, 冼绍祥, 等. 从肺论治心力衰竭大鼠左室心肌的重构[J]. 新中医, 2016, 48(7):278-282. |